NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球生物類似藥市場:行業趨勢、市場份額/規模/增長率/機遇和預測(2021-2026)

Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版商 IMARC Services Private Limited 商品編碼 1006931
出版日期 內容資訊 英文 148 Pages
商品交期: 2-3個工作天內
價格
全球生物類似藥市場:行業趨勢、市場份額/規模/增長率/機遇和預測(2021-2026) Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
出版日期: 2021年05月20日內容資訊: 英文 148 Pages
簡介

2020年全球生物類似藥市場規模達到77億美元。目前市場受多種因素驅動,包括重磅生物製藥專利到期、價格下跌、慢性病流行、政府削減成本舉措和第三方支付方。由於這些因素,預計未來五年市場將強勁增長。生物仿製藥,也稱為生物仿製藥,是與對照生物製藥非常相似的生物製藥。它是用活的有機體和細胞製成的,具有複雜的分子結構。當生物製藥專利到期時,製藥商將在獲得監管批准的情況下開始生產生物仿製藥。為了被標記為生物仿製藥,生物製藥必須在質量、安全性和有效性方面證明相似。與仿製藥相比,生物仿製藥價格昂貴,因為它們的製造過程更複雜,需要更多的研發投資。

全球生物仿製藥市場增長/限制因素:

  • 多年來,一些重磅生物藥的專利已經到期,預計未來幾年會有更多超大新藥失去專利保護。預計這將在不久的將來為生物仿製藥製造商提供重要的機會。
  • 政府和第三方支付機構的成本削減努力推動了生物仿製藥的使用,而不是品牌生物製藥,這推動了對生物仿製藥的需求。
  • 推動生物仿製藥需求的其他因素包括成本效益、慢性病(如自身免疫性疾病和癌症)的患病率增加以及老年人口的增加。
  • 對醫生的負面看法、專利延期以及與低分子量仿製藥相比的低價差是阻礙生物仿製藥市場增長的因素。

本報告調查了全球生物類似藥市場,並提供了有關行業趨勢、市場預測、按分子/製造商類型/適應症/地區劃分的市場分析、競爭形勢、主要公司簡介等信息。

目錄

第 1 章前言

第 2 章範圍和調查方法

第 3 章執行摘要

第 4 章生物類似藥市場-介紹

  • 概述
  • WHO 和 FDA 的生物仿製藥術語
  • 生物仿製藥和仿製藥
  • 生物仿製藥和品牌生物製藥

第 5 章生物仿製藥的好處

  • 重磅生物製藥專利到期
  • 生物仿製藥與創新藥價格差異巨大
  • 為政府和第三方付款人節省開支
  • 生活方式相關疾病的患病率增加
  • 對處方者、藥劑師和患者的激勵
  • 歐洲和新興市場的新興初創企業
  • 製造商與藥物輸送設備公司合作以區分他們的產品

第 6 章生物類似藥的研究、開發與製造

  • 研發:生物仿製藥和創新藥物
  • 製造業:生物仿製藥和創新藥物

第 7 章生物類似藥市場

  • 市場概覽
  • 過去的成就
  • COVID-19 的影響
  • 按細分市場細分
  • 按製造商劃分的市場細分
  • 按適應症細分市場
  • 區域市場細分
  • 生物類似藥專利情況
    • 美國專利情況
    • 歐洲專利情況
    • 日本專利情況
  • SWOT 分析
    • 概述
    • 優勢
    • 弱點
    • 市場機會
    • 威脅
  • 價值鏈分析
    • 現有創新藥物的表徵
    • 研發
    • 產品開發
    • 最終產品處方
    • 營銷和分銷
  • 波特五力分析
  • 價格分析
    • 主要價格指標
    • 價格趨勢
    • 保證金分析

第 8 章分子市場細分

  • Infliximab
  • Insulin Glargine
  • Epoetin Alfa
  • Etanercept
  • Filgrastim
  • Somatropin
  • Rituximab
  • Follitropin Alfa

第 9 章按製造商類型劃分的市場細分

  • 內部製造
  • 代工製造

第 10 章按適應症劃分的市場

  • 自身免疫性疾病
  • 血液病
  • 糖尿病
  • 腫瘤學
  • 成長失敗
  • 女性不孕症

第 11 章按地區劃分的市場細分

  • 歐洲
    • 市場表現
    • 主要公司和生物仿製藥
    • 國家市場細分
    • 意大利
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他歐洲
  • 美國
    • 當前市場趨勢
    • 主要公司和生物仿製藥
  • 日本
    • 市場表現
    • 主要公司和生物仿製藥
  • 印度
    • 當前市場趨勢
    • 主要公司和生物仿製藥
  • 韓國
    • 當前市場趨勢
    • 主要公司和生物仿製藥
  • 其他領域
    • 當前市場趨勢

第 12 章安裝生物類似藥製造工廠的要求

  • 製造過程
  • 原材料要求
  • 原材料
  • 土地和建設要求
  • 機械和基礎設施要求
  • 機器
  • 工廠佈局
  • 包裝要求
  • 實用程序要求
  • 人員要求

第 13 章競爭形勢

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • Novartis
    • Pfizer
    • Teva
    • Celltrion
    • Merck & Co
    • Samsung Bioepis
    • Eli Lilly
    • Biocon
    • Amgen
    • Dr. Reddy's Laboratories
    • Boehringer Ingelheim

圖列表

圖 17 Filgrastim:生物仿製藥市場:銷售額(100 萬美元),2012-2017 年

表列表

目錄
Product Code: SR1020C10_Report

The biosimilar market reached a value of US$ 7.7 Billion in 2020. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market is expected to witness strong growth during the next five years.Biosimilars, also known as follow-on biologics, refers to a biotherapeutic product which is highly similar to a reference biologic drug. It is produced using living organisms or cells and has a complex molecular structure. When the patent of a biologic drug expires, manufacturers resort to the approval from the regulatory authorities so as to start the production of biosimilars. For being labelled as a biosimilar, a biological drug should be proved similar in terms of quality, safety and efficacy. In comparison with generic drugs, biosimilars are expensive as their production process is more complex and requires higher investment in research and development.

Global Biosimilar Market Drivers/Constraints:

  • Over the years, the patents of several blockbuster biologic drugs have expired and a number of blockbuster drugs are further expected to lose patent protection in the coming years. This is expected to provide tremendous opportunities for biosimilar manufacturers in the near future.
  • Cost-saving initiatives undertaken by governments and third-party payers have encouraged the use of biosimilars over branded biologics, thereby propelling the demand of biosimilars.
  • Some of the other factors bolstering the demand for biosimilars include cost-effectiveness, rising prevalence of chronic diseases (such as autoimmune diseases and cancer) and growing geriatric population.
  • There are some factors hampering the growth of the biosimilars market. This includes negative perception from physicians, patent extensions, lower price differential compared to small-molecule generics, etc.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global biosimilar market report, along with forecasts for growth at the global, regional and country-level from 2021-2026. Our report has categorized the market based on region, molecule insights, indication insights, and manufacturing insights.

Molecule insights:

  • On the basis of molecule, the market has been segmented as Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, etc. Currently, Infliximab dominates the market, holding the largest share.

Indication Insights:

  • Based on the indication, autoimmune diseases account for the majority of the total market share. Other major indications include oncology, diabetes, blood disorder, growth deficiency, female infertility, etc.

Manufacturing Insights:

  • Based on the type of manufacturing, the market is segregated into in-house manufacturing and contract manufacturing. Amongst these, in-house manufacturing accounts for the majority of the market share.

Regional Insights:

  • Region-wise, the market has been segmented into the United States, Germany, France, Italy, Spain, United Kingdom, Japan, India, South Korea and Others.

Competitive Landscape:

The competitive landscape of the global biosimilar market has also been analysed. Some of the leading players operating in the market are:

  • Novartis
  • Pfizer
  • Teva
  • Celltrion
  • Merck & Co
  • Samsung Bioepis
  • Eli Lilly
  • Biocon
  • Dr. Reddy's Laboratories
  • Amgen
  • Boehringer Ingelheim
  • This report provides a deep insight into the global biosimilars market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the biosimilars market in any manner.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Biosimilar Market - Introduction

  • 4.1 Overview
  • 4.2 WHO and FDA Terminology on Biosimilars
  • 4.3 Biosimilars and Generics
  • 4.4 Biosimilars and Branded Biological Products

5 Why are Biosimilars So Lucrative?

  • 5.1 Patent Expiry of Blockbuster Biological Drugs
  • 5.2 Significant Price Differential between Biosimilars and Innovator Drugs
  • 5.3 Savings for the Government and Third Party Payers
  • 5.4 Rising Prevalence of Lifestyle Diseases
  • 5.5 Incentives for Prescribers, Pharmacists and Patients
  • 5.6 Emergence of New Players in Europe and Emerging Markets
  • 5.7 Increasing Product Differentiation as Manufacturers Tie-Up with Drug Delivery Device Companies

6 Biosimilar Research, Development and Manufacturing

  • 6.1 Research and Development: Biosimilars vs. Innovator Drugs
  • 6.2 Manufacturing: Biosimilars vs. Innovator Drugs

7 Biosimilar Market

  • 7.1 Market Overview
  • 7.2 Historical Performance
  • 7.3 Impact of COVID-19
  • 7.4 Market Breakup by Segment
  • 7.5 Market Breakup by Manufacturer Type
  • 7.6 Market Breakup by Indication
  • 7.7 Market Breakup by Region
  • 7.8 Market Forecast
  • 7.9 Biosimilar Patent Landscape
    • 7.9.1 Patent Landscape in the US
    • 7.9.2 Patent Landscape in Europe
    • 7.9.3 Patent Landscape in Japan
  • 7.10 SWOT Analysis
    • 7.10.1 Overview
    • 7.10.2 Strengths
    • 7.10.3 Weaknesses
    • 7.10.4 Opportunities
    • 7.10.5 Threats
  • 7.11 Value Chain Analysis
    • 7.11.1 Characterizing the Existing Innovator Drug
    • 7.11.2 Research and Development
      • 7.11.2.1 Characterization of Biosimilars
      • 7.11.2.2 Developing a Unique Cell Line
    • 7.11.3 Product Development
      • 7.11.3.1 Pre-Testing
      • 7.11.3.2 Intermediary Clinical Testing (PK/PD)
      • 7.11.3.3 Confirmatory Clinical Phase-III
    • 7.11.4 Final Product Formulation
    • 7.11.5 Marketing and Distribution
  • 7.12 Porter's Five Forces Analysis
    • 7.12.1 Overview
    • 7.12.2 Bargaining Power of Buyers
    • 7.12.3 Bargaining Power of Suppliers
    • 7.12.4 Degree of Competition
    • 7.12.5 Threat of New Entrants
    • 7.12.6 Threat of Substitutes
  • 7.13 Price Analysis
    • 7.13.1 Key Price Indicators
    • 7.13.2 Price Trends
    • 7.13.3 Margin Analysis

8 Market Breakup by Molecule

  • 8.1 Infliximab
  • 8.2 Insulin Glargine
  • 8.3 Epoetin Alfa
  • 8.4 Etanercept
  • 8.5 Filgrastim
  • 8.6 Somatropin
  • 8.7 Rituximab
  • 8.8 Follitropin Alfa

9 Market Breakup by Type of Manufacturing

  • 9.1 In-house Manufacturing
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Contract Manufacturing
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Indication

  • 10.1 Auto-Immune Diseases
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Blood Disorder
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Diabetes
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Oncology
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Growth Deficiency
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast
  • 10.6 Female Infertility
    • 10.6.1 Market Trends
    • 10.6.2 Market Forecast

11 Market Breakup by Region

  • 11.1 Europe
    • 11.1.1 Market Performance
    • 11.1.2 Key Players and Biosimilars
    • 11.1.3 Market Breakup by Country
    • 11.1.4 Market Forecast
    • 11.1.5 Italy
      • 11.1.5.1 Market Performance
      • 11.1.5.2 Key Players and Biosimilars
      • 11.1.5.3 Market Forecast
    • 11.1.6 Germany
      • 11.1.6.1 Market Performance
      • 11.1.6.2 Key Players and Biosimilars
      • 11.1.6.3 Market Forecast
    • 11.1.7 France
      • 11.1.7.1 Market Performance
      • 11.1.7.2 Key Players and Biosimilars
      • 11.1.7.3 Market Forecast
    • 11.1.8 United Kingdom
      • 11.1.8.1 Market Performance
      • 11.1.8.2 Key Players and Biosimilars
      • 11.1.8.3 Market Forecast
    • 11.1.9 Spain
      • 11.1.9.1 Market Performance
      • 11.1.9.2 Key Players and Biosimilars
      • 11.1.9.3 Market Forecast
    • 11.1.10 Rest of Europe
      • 11.1.10.1 Market Performance
      • 11.1.10.2 Market Forecast
  • 11.2 United States
    • 11.2.1 Current Market Trends
    • 11.2.2 Key Players and Biosimilars
    • 11.2.3 Market Forecast
  • 11.3 Japan
    • 11.3.1 Market Performance
    • 11.3.2 Key Players and Biosimilars
    • 11.3.3 Market Forecast
  • 11.4 India
    • 11.4.1 Current Market Trends
    • 11.4.2 Key Players and Biosimilars
    • 11.4.3 Market Forecast
  • 11.5 South Korea
    • 11.5.1 Current Market Trends
    • 11.5.2 Key Players and Biosimilars
    • 11.5.3 Market Forecast
  • 11.6 Rest of the World
    • 11.6.1 Current Market Trends
    • 11.6.2 Market Forecast

12 Requirements for Setting Up a Biosimilar Manufacturing Plant

  • 12.1 Manufacturing Process
  • 12.2 Raw Material Requirements
  • 12.3 Raw Material Pictures
  • 12.4 Land and Construction Requirements
  • 12.5 Machinery and Infrastructure Requirements
  • 12.6 Machinery Pictures
  • 12.7 Plant Layout
  • 12.8 Packaging Requirements
  • 12.9 Utility Requirements
  • 12.10 Manpower Requirements

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Novartis
    • 13.3.2 Pfizer
    • 13.3.3 Teva
    • 13.3.4 Celltrion
    • 13.3.5 Merck & Co
    • 13.3.6 Samsung Bioepis
    • 13.3.7 Eli Lilly
    • 13.3.8 Biocon
    • 13.3.9 Amgen
    • 13.3.10 Dr. Reddy's Laboratories
    • 13.3.11 Boehringer Ingelheim

List of Figure

  • Figure 1: Global: Biosimilar Market: Sales Value (in Billion US$), 2015-2020
  • Figure 2: Global: Biosimilar Market: Breakup by Molecule (in %), 2020
  • Figure 3: Global: Biosimilar Market: Breakup by Manufacturer (in %), 2020
  • Figure 4: Global: Biosimilar Market: Breakup by Indication (in %), 2020
  • Figure 5: Global: Biosimilar Market: Breakup by Region (in %), 2020
  • Figure 6: Global: Biosimilar Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 7: Global Biosimilars Industry: SWOT Analysis
  • Figure 8: Global: Biosimilar Industry: Value Chain Analysis
  • Figure 9: Global: Biosimilars Industry: Porter's Five Forces Analysis
  • Figure 10: Global: Biosimilar Market: Average Price Trends of Inflectra
  • Figure 11: Global: Biosimilar Market: Average Price Trends of Zarxio
  • Figure 12: Biosimilars Industry: Breakup of Profit Margins at Various Level of the Value Chain
  • Figure 13: Rituximab: Biosimilar Market: Sales Value (in Million US$), 2016 & 2017
  • Figure 14: Infliximab: Biosimilar Market: Sales Value (in Million US$), 2015 - 2017
  • Figure 15: Insulin Glargine: Biosimilar Market: Sales Value (in Million US$), 2016 & 2017
  • Figure 16: Epoetin Alfa: Biosimilar Market: Sales Value (in Million US$), 2012 - 2017

Figure 17 Filgrastim: Biosimilar Market: Sales Value (in Million US$), 2012 - 2017

  • Figure 18: Somatropin: Biosimilar Market: Sales Value (in Million US$), 2012 - 2017
  • Figure 19: Etanercept: Biosimilar Market: Sales Value (in Million US$), 2016 & 2017
  • Figure 20: Follitropin Alfa: Biosimilar Market: Sales Value (in Million US$), 2015 - 2017
  • Figure 21: In-House Manufacturing: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 22: In-House Manufacturing: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Contract Manufacturing: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 24: Contract Manufacturing: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: Global: Biosimilar Market (Autoimmune Diseases): Sales Value (in Million US$), 2015 & 2020
  • Figure 26: Global: Biosimilar Market Forecast (Autoimmune Diseases): Sales Value (in Million US$), 2021-2026
  • Figure 27: Global: Biosimilar Market (Blood Disorders): Sales Value (in Million US$), 2015 & 2020
  • Figure 28: Global: Biosimilar Market Forecast (Blood Disorders): Sales Value (in Million US$), 2021-2026
  • Figure 29: Global: Biosimilar Market (Diabetes): Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Global: Biosimilar Market Forecast (Diabetes): Sales Value (in Million US$), 2021-2026
  • Figure 31: Global: Biosimilar Market (Oncology): Sales Value (in Million US$), 2015 & 2020
  • Figure 32: Global: Biosimilar Market Forecast (Oncology): Sales Value (in Million US$), 2021-2026
  • Figure 33: Global: Biosimilar Market (Growth Deficiency): Sales Value (in Million US$), 2015 & 2020
  • Figure 34: Global: Biosimilar Market Forecast (Growth Deficiency): Sales Value (in Million US$), 2021-2026
  • Figure 35: Global: Biosimilar Market (Female Infertility): Sales Value (in Million US$), 2015 & 2020
  • Figure 36: Global: Biosimilar Market Forecast (Female Infertility): Sales Value (in Million US$), 2021-2026
  • Figure 37: Europe: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 38: Europe: Biosimilar Market: Breakup by Country (in %), 2020
  • Figure 39: Europe: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 40: Italy: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 41: Italy: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 42: Germany: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 43: Germany: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 44: France: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 45: France: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 46: United Kingdom: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 47: United Kingdom: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 48: Spain: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 49: Spain: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 50: Rest of Europe: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 51: Rest of Europe: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 52: United States: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 53: United States: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 54: Japan: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 55: Japan: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 56: India: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 57: India: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 58: South Korea: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 59: South Korea: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 60: Others: Biosimilar Market: Sales Value (in Million US$), 2015-2020
  • Figure 61: Others: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 62: Biosimilar Manufacturing: Detailed Process Flow
  • Figure 63: Biosimilar Manufacturing Plant: Raw Materials Requirement
  • Figure 64: Biosimilar Manufacturing Process: Conversion Rates of Feedstocks
  • Figure 65: Biosimilar Manufacturing Plant: Machinery Costs (in US$)
  • Figure 66: Biosimilar Manufacturing Plant: Primary Packaging
  • Figure 67: Biosimilar Manufacturing Plant: Secondary Packaging
  • Figure 68: Biosimilar Manufacturing Plant: Tertiary Packaging

List of Table

  • Table 1: Global: Sales and Patent Expiry of Blockbuster Biological Drugs (in Million US$), 2017
  • Table 2: Global: Biosimilar Market: Biosimilars Vs Innovators Drug Development
  • Table 3: Global: Biosimilar Market: Biosimilars Vs Biologics Manufacturing
  • Table 4: Global: Biosimilar Market: Key Industry Highlights, 2020 and 2026
  • Table 5: US: Biosimilar Market: Patent Landscape
  • Table 6: Europe: Biosimilar Market: Patent Landscape
  • Table 7: Japan: Biosimilar Market: Patent Landscape
  • Table 8: Global: Biosimilar Market: Price Comparison Between Biosimilar and Originator Drugs
  • Table 9: Global: Biosimilar Market: Breakup by Molecule (in Million US$), 2012-2017
  • Table 10: Global: Rituximab: Brand & Biosimilar Market Overview
  • Table 11: Global: Infliximab: Brand & Biosimilar Market Overview
  • Table 12: Global: Insulin Glargine: Brand & Biosimilar Market Overview
  • Table 13: Global: Epoetin Alfa: Brand & Biosimilar Market Overview
  • Table 14: Global: Filgrastim: Brand & Biosimilar Market Overview
  • Table 15: Global: Somatropin: Brand & Biosimilar Market Overview
  • Table 16: Global: Etanercept: Brand & Biosimilar Market Overview
  • Table 17: Global: Follitropin Alfa: Brand & Biosimilar Market Overview
  • Table 18: Global: Biosimilar Market Forecast: Breakup by Manufacturing Type (in Million US$), 2021-2026
  • Table 19: Global: Biosimilar Market Forecast: Breakup by Indication (in Million US$), 2021-2026
  • Table 20: Global: Biosimilar Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 21: Europe: Biosimilar Market: Key Players and Biosimilars
  • Table 22: Italy: Biosimilar Market: Key Players and Biosimilars
  • Table 23: Germany: Biosimilar Market: Key Players and Biosimilars
  • Table 24: France: Biosimilar Market: Key Players and Biosimilars
  • Table 25: United Kingdom: Biosimilar Market: Key Players and Biosimilars
  • Table 26: Spain: Biosimilar Market: Key Players and Biosimilars
  • Table 27: United States: Biosimilar Market: Key Players and Biosimilar
  • Table 28: United States: Biosimilar Market: Launch of Expected Biosimilar
  • Table 29: Japan: Biosimilar Market: Key Players and Biosimilars
  • Table 30: India: Biosimilar Market: Key Players and Biosimilars
  • Table 31: South Korea: Biosimilar Market: Key Players and Biosimilar
  • Table 32: Biosimilar Manufacturing Plant: Manpower Requirements
  • Table 33: Biosimilar Market: Competitive Structure
  • Table 34: Global: Biosimilar Market: Key Players